At Helmsley, we believe that autoantibody screening for type 1 diabetes (T1D) and follow-up monitoring of affected children should be part of providing quality pediatric clinical care.

To support adoption of these measures we funded a landscape analysis and strategy development by the Milken Institute’s Center for Strategic Philanthropy titled “Type 1 Diabetes Autoantibody Screening: A Roadmap for Pediatric Policy Implementation.”

Learn more about this initiative and T1D screening from Helmsley Type 1 Diabetes Program Officer Anne Koralova, PhD in her interview with T1D Exchange.